On the evening of August 29, Tonghua Jinma announced that the company recently received the State Drug Administration issued a listing application for succinium octahydroaminoacridine tablets “Notice of Acceptance”, the oral drug for light, moderate Alzheimer's disease (Alzheimer's disease, AD) treatment. On the same day, Tonghua Jinma plate rushed to a halt, closing up 9.98%, closing price of 14.54 yuan / share.

Alzheimer's disease as one of the most common neurodegenerative diseases, the number of its patients with the aging trend of the population and rising.

According to the introduction, Succinum Octahydroaminoacridine Tablets is a new, potent, clear mechanism of action of cholinesterase inhibitors, is a new chemical 1 class of drugs with complete independent intellectual property rights, new chemical molecular structure, domestic and foreign have not been marketed. The results of the main pharmacodynamic study show that the drug exhibits strong inhibition of both acetylcholinesterase and butyrylcholinesterase, and by inhibiting cholinesterase, it can increase the content of acetylcholine in the brain, and it is mainly used in the treatment of mild and moderate Alzheimer's disease.

Tonghua Jinma said, the next step, the company will continue to increase the research and development of new drugs of chemical 1, focusing on the top international and domestic R & D resources to carry out clinical research, relying on Alzheimer's disease strategic development research committee as a technical exchange platform, to further carry out in-depth research and development. In addition, the company will rely on its own powerful medical resources, innovative treatment and disease management concepts, to build an AD industry chain system integrating “screening, diagnosis, treatment, care and rehabilitation” for Alzheimer's disease.

“The independent research and development of Succinum Octahydroaminoacridine Tablets has been going on for nearly 20 years, and has gathered the efforts and wisdom of countless researchers.” Tonghua Jinma said that the company will make every effort to promote the registration and listing of the drug in China, and strive to provide safer, more effective and more cost-effective treatment options for relevant patients at an early date.

https://www.thjm.cn/page/3.htm